Key takeaway #1: This article responds to Scott and @RCarhartHarris's recent proposal to use psilocybin as a treatment for DoC patients. We commend Scott and @RCarhartHarris for exploring new therapies for this population. Their proposal is linked here:https://academic.oup.com/nc/article/2019/1/niz003/5475888#.XZ44E9FNicE.twitter …
-
-
Prikaži ovu nit
-
Key takeaway #2: We argue first that Ariella Binik and
@SpencerPHey's 'Value-Validity Framework' should be applied to new drug trials involving DoC patients.Prikaži ovu nit -
Key takeaway #2: We argue second that
@charlesweijer and Paul Miller's 'Component Analysis' should be applied to new drug trials involving DoC patients.Prikaži ovu nit -
Key takeaway #3: We question whether psilocybin administration in DoC patients poses "no more than a minor increase over minimal risk", consistent with the
@medwma standards for non-therapeutic research interventions in vulnerable populations.Prikaži ovu nit -
Key takeaway #4: We provide a number of practical recommendations for researchers who are interested in proposing a psilocybin trial in DoC patients (or other similar vulnerable populations). We believe these recommendations will help to improve the science of consciousness.
Prikaži ovu nit -
We thank: Tim Bayne and
@damiancruse for helpful discussion on the ideas contained in this paper. We also thank@NeuroConsc editors,@anilkseth and@hohwy, for supporting publication of a research ethics analysis in the journal.Prikaži ovu nit
Kraj razgovora
Novi razgovor -
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.